KLEENRESOURCE

Their commercial start date is 01/01/2016. The global infection control market is estimated to reach $16.7 Billion by 2020, growing at a CAGR of 6.7% during the forecast period (2015 to 2020). The rise in chronic diseases, increase in the number of surgeries performed, increase in the occurrence of hospital-acquired infections, and aging population are the major drivers for the growth of infection control market. KleenResource is the product of world-class technology in the hands of a prov... en management team. The increasing need to eradicate harmful bacteria in the US and the thorough performance of KleenResource technology applications present an ideal market opportunity for investors. KleenResource is striving to become the “go to” provider for ambulance sterilization services in the US. KleenResource services improve health conditions for personnel in the Emergency Medical Technician industry and for patients to which they provide services. Infectious bacteria exposure is sharply diminished through use of the patent pending KleenResource ozone-based sterilization service. Regularly scheduled sterilization with their system creates an insurvivable environment for bacteria. KleenResource’s technology partner, Genlantis has provided ozone-based equipment into medical research laboratories and other scientifically critical applications for some time. KleenResource owns an exclusive license for this Genlantis technology application. EMT service personnel deserve “best in class” protection and prevention, as do the patients they serve. Public health is materially improved through these green and sustainable services. Ozone is a natural gas and is a product of electricity and oxygen. No chemicals are involved. Included in their materials is a ""kill list” of bacterial strains that are eradicated via their services. Common staph microorganisms including MRSA and hundreds more esoteric and no less dangerous strains are eliminated.More